KRAS and pancreatic neoplasm: Lorlatinib was also able to extend the survival of a genetically engineered PDAC mouse model that expresses mutant alleles of Kras and Tp53 and develop pancreatic tumors whose pathophysiological and molecular features resemble those of human PDAC.